These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25461233)

  • 1. In brief: topiramate extended-release capsules (Qudexy XR).
    Med Lett Drugs Ther; 2014 Dec; 56(1457):e126. PubMed ID: 25461233
    [No Abstract]   [Full Text] [Related]  

  • 2. Topiramate extended-release (Trokendi XR) for epilepsy.
    Med Lett Drugs Ther; 2013 Oct; 55(1428):87-8. PubMed ID: 24165709
    [No Abstract]   [Full Text] [Related]  

  • 3. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.
    Anderson GD; Saneto RP
    CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity to topiramate sprinkle capsules does not preclude the use of topiramate tablets.
    Marsden D; Libretto SE
    Paediatr Drugs; 2004; 6(2):133-5. PubMed ID: 15035654
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
    Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of type IV hypersensitivity to topiramate and carbamazepine.
    Schiavino D; Nucera E; Buonomo A; Musumeci S; Pollastrini E; Roncallo C; Lombardo C; Alonzi C; Pecora V; Corradini C; De Pasquale T; Patriarca G
    Contact Dermatitis; 2005 Mar; 52(3):161-2. PubMed ID: 15811034
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world assessment of treatment with extended-release topiramate (Trokendi XR
    O'Neal W; Hur EE; Liranso T; Patel B
    J Comp Eff Res; 2018 Nov; 7(11):1095-1105. PubMed ID: 30136603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamotrigine extended-release as adjunctive therapy for partial seizures.
    Naritoku DK; Warnock CR; Messenheimer JA; Borgohain R; Evers S; Guekht AB; Karlov VA; Lee BI; Pohl LR
    Neurology; 2007 Oct; 69(16):1610-8. PubMed ID: 17938371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of refractory neonatal seizures with topiramate.
    Riesgo R; Winckler MI; Ohlweiler L; Ranzan J; Becker M; Salvador S; Magalhaes L; Ribeiro R
    Neuropediatrics; 2012 Dec; 43(6):353-6. PubMed ID: 23007795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.
    Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC
    Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate: A Review of Analytical Approaches for the Drug Substance, Its Impurities and Pharmaceutical Formulations.
    Pinto EC; Dolzan MD; Cabral LM; Armstrong DW; de Sousa VP
    J Chromatogr Sci; 2016 Feb; 54(2):280-90. PubMed ID: 26276847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anticonvulsant and psychotropic effects of topamax capsules].
    Kalinin VV; Zheleznova EV; Sokolova LV; Zemlianaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12):80-4. PubMed ID: 20037527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate can induce hypoadrenalism in patients taking oral corticosteroid replacement.
    Jacob K; Trainer PJ
    BMJ; 2009 Jan; 338():a1788. PubMed ID: 19131388
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media.
    Smith AP; Moore TW; Westenberger BJ; Doub WH
    Int J Pharm; 2010 Oct; 398(1-2):93-6. PubMed ID: 20667505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation.
    Chen C; Wright J; Gidal B; Messenheimer J
    Ther Drug Monit; 2013 Apr; 35(2):188-93. PubMed ID: 23503444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pharmacology of topiramate: managing seizures and preventing migraine.
    White HS
    Headache; 2005 Apr; 45 Suppl 1():S48-56. PubMed ID: 15833090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate efficacy in an infant with partial seizures refractory to conventional antiepileptic drugs.
    Veggiotti P; Longaretti F; Signorini S; Cardinali S; Lanzi G
    Seizure; 2004 Jun; 13(4):241-3. PubMed ID: 15121132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy.
    Wechsler RT; Leroy R; Van Cott A; Hammer AE; Vuong A; Huffman R; VanLandingham K; Messenheimer JA
    Epilepsy Res; 2014 Aug; 108(6):1128-36. PubMed ID: 24888248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.
    Lambrecht LJ; Shekh-Ahmad T; Todd WM; Halvorsen MB; Bialer M
    Epilepsia; 2011 Oct; 52(10):1877-83. PubMed ID: 21770925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.